0
Anavex Life Sciences Corp. Banner Image

Anavex Life Sciences Corp. has reached its limit for free report views

Work for Anavex Life Sciences Corp.? Upgrade Your Profile and unlock all your annual reports.

Anavex Life Sciences Corp.

  • Ticker AVXL
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Anavex Life Sciences Corp. Logo Image
  • 11-50 Employees
  • Based in New York City, New York
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drugMore candidate, ANAVEX®2-73 (blarcamesine), recently completed a successful Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy.
Anavex Life Sciences Corp.

Most Recent Annual Report

Anavex Life Sciences Corp. MOST RECENT 2019 Form 10K

Report Locked. Anavex Life Sciences Corp. has reached its limit for free report views.